Oppenheimer cut shares of aTyr Pharma ( NASDAQ:LIFE – Free Report ) from an outperform rating to a market perform rating in a report published on Wednesday morning, MarketBeat Ratings reports. A number of other equities research analysts have also recently commented on the stock. HC Wainwright reiterated a buy rating and issued a $35.00 target price on shares of aTyr Pharma in a research report on Friday, March 10th. Piper Sandler lifted their price objective on shares of aTyr Pharma from $9.

https://www.dailypolitical.com/2023/07/08/atyr-pharma-nasdaqlife-downgraded-to-market-perform-at-oppenheimer.html

#dailypolitical